# Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder

> **NCT01379625** · PHASE2 · COMPLETED · sponsor: **Oregon Health and Science University** · enrollment: 32 (actual)

## Conditions studied

- Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency
- Carnitine Palmitoyltransferase 2 (CPT2) Deficiency
- Mitochondrial Trifunctional Protein (TFP) Deficiency
- Long-chain 3 hydroxyacylCoA Dehydrogenase (LCHAD) Deficiency

## Interventions

- **DRUG:** Triheptanoin

## Key facts

- **NCT ID:** NCT01379625
- **Lead sponsor:** Oregon Health and Science University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01379625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01379625, "Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01379625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*